MOTIF BIO PLC/S (NASDAQ:MTFB) and Skinvisible (OTCMKTS:SKVI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
This table compares MOTIF BIO PLC/S and Skinvisible’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|MOTIF BIO PLC/S||N/A||N/A||N/A|
Insider and Institutional Ownership
7.4% of MOTIF BIO PLC/S shares are held by institutional investors. 53.0% of Skinvisible shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares MOTIF BIO PLC/S and Skinvisible’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MOTIF BIO PLC/S||N/A||N/A||-$44.81 million||($0.19)||-52.95|
Skinvisible has higher revenue and earnings than MOTIF BIO PLC/S.
This is a summary of recent ratings and price targets for MOTIF BIO PLC/S and Skinvisible, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|MOTIF BIO PLC/S||0||1||2||0||2.67|
MOTIF BIO PLC/S currently has a consensus price target of $32.00, indicating a potential upside of 218.09%. Given MOTIF BIO PLC/S’s higher possible upside, equities research analysts clearly believe MOTIF BIO PLC/S is more favorable than Skinvisible.
Risk & Volatility
MOTIF BIO PLC/S has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Skinvisible has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.
About MOTIF BIO PLC/S
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic markets. Its non-dermatological formulations offer solutions for women's health, pain management, and others markets. The company offers sunless tanning, anti-aging, and sunscreen products. Skinvisible, Inc. also licenses its products to manufacturers and marketers of brands internationally, as well as sells directly in the market; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was founded in 1998 and is based in Las Vegas, Nevada.
Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.